CVS Health
CVS
$87.95
+1.76%
CVS Health is a diversified healthcare conglomerate whose operations span retail pharmacy (roughly 9,000 US stores), a top-tier pharmacy benefit manager (Caremark, processing about 2 billion adjusted claims annually), a major health insurer (Aetna, serving approximately 26 million medical members), and an expanding primary care platform built around the Oak Street Health acquisition. Its distinct competitive identity rests on vertical integration — an unmatched combination of pharmacy counter, PBM, and insurance assets that lets it capture economics across the drug supply chain and steer members toward lower-cost care settings. The current investor narrative centers on a credible turnaround: a favorable CMS Medicare Advantage rate decision worth roughly $13 billion in added revenue, a lower medical cost ratio that lifted Q1 2026 profits and full-year guidance, and management's push to embed AI and consumer wellness offerings across the enterprise. That optimism is now being tested by persistent reimbursement pressure, regulatory scrutiny of PBM practices, and a sharp late-summer share-price pullback that has reopened the debate over whether the recovery is durable or merely cyclical.…
CVS
CVS Health
$87.95
Related headlines
Investment Opinion: Should I buy CVS Today?
The synthesized recommendation for CVS is a Hold with a positive bias, reflecting a balance between deep value and near-term uncertainty. The core thesis is that CVS is a deeply undervalued healthcare conglomerate with a credible earnings recovery, but persistent reimbursement pressures and regulatory risks warrant caution until the turnaround proves durable. The analyst consensus is 'strong_buy' with an average target of $116.28, implying 34.5% upside, but the stock's recent price action suggests the market is not yet convinced.
Supporting evidence includes the forward PE of 10.14x, which is well below the historical range of 8–23x and the broader market, and a PS ratio of 0.25x that sits at the bottom of its multi-year range. Revenue grew 7.26% year-over-year in Q2 2026 to $106.10 billion, and net income inflected to $2.995 billion from a loss in the prior-year quarter. Free cash flow of $11.76 billion comfortably covers the 3.38% dividend yield, and the company has a strong analyst consensus with 25 analysts covering it. However, gross margin remains thin at 14.84%, and the debt-to-equity ratio of 1.24 adds financial risk.
The biggest risks that could invalidate the thesis are a regulatory crackdown on PBM practices, a sustained increase in medical cost ratios, and a failure to achieve the projected EPS of $11.75. The rating would upgrade to Buy if the stock reclaims $95–$100 and forward EPS estimates are raised, or downgrade to Sell if revenue growth decelerates below 5% or if the medical cost ratio rises significantly. Relative to its history and peers, CVS appears undervalued, but the market is pricing in substantial execution risk, so the stock is fairly valued until clearer signs of sustainable recovery emerge.
Sign up to view all
CVS 12-Month Price Forecast
CVS presents a classic value-versus-momentum dilemma. The forward valuation is compelling at 10.14x earnings, and the analyst community is overwhelmingly bullish with a $116.28 average target. However, the stock's recent price action and relative weakness suggest the market is skeptical of the recovery, and structural headwinds in reimbursement and regulation remain. The base case (50% probability) sees the stock trading toward $103–$116 as earnings gradually improve, but the bear case (20%) risks a retest of the 52-week low. I would upgrade to bullish if the stock reclaims $95–$100 with improving volume and forward EPS estimates are revised upward; I would downgrade to bearish if it breaks below $85 or if medical cost ratios deteriorate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CVS Health's 12-month outlook, with a consensus price target around $115.76 and implied upside of +31.6% versus the current price.
Average Target
$115.76
0 analysts
Implied Upside
+31.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$103 - $145
Analyst target range
Coverage is robust with 25 analysts, and sentiment is decisively bullish: the consensus recommendation is "strong_buy" with a recommendation mean of 1.41 (where 1.0 is a strong buy). The average target price of $116.28 implies roughly +34.5% upside from the current $86.46, a wide gap that reflects analyst conviction that the recent selloff is overdone relative to fundamental improvement. Estimated EPS averages of $11.75 (range $11.34–$12.26) and estimated revenue of $491.9 billion provide the earnings base underpinning those targets.
The target range spans $103.00 to $148.00 — a $45 spread, or roughly 39% of the average target — signaling meaningful disagreement about the pace of recovery. The high target of $148.00 implies multiple expansion toward 12–13x forward earnings plus successful execution on Medicare Advantage margin recovery and PBM stabilization, while the low target of $103.00 (still +19% above spot) prices in only modest re-rating and continued reimbursement pressure. Institutional ratings show a uniformly constructive tone with no downgrades: UBS, Argus, JP Morgan, Barclays, Evercore ISI, Truist, Wells Fargo, and RBC all maintained Buy/Overweight/Outperform ratings between July and September 2026, suggesting the analyst community views the 17% three-month decline as a buying opportunity rather than a thesis break — though the stock's failure to respond to that consensus support is itself a cautionary signal about market skepticism.
Bulls vs Bears: CVS Investment Factors
The bull case rests on deep value (10.14x forward PE, 0.25x PS), strong analyst support (34.5% upside to $116.28 average target), and a clear profitability inflection from the Q3 2025 loss to Q2 2026 net income of $2.995 billion. The bear case emphasizes the severe recent momentum breakdown (-17.44% over three months), structurally thin margins (14.84% gross), a leveraged balance sheet (1.24 debt-to-equity, 0.84 current ratio), and persistent regulatory headwinds. Currently, the bear evidence has stronger near-term weight because the stock's price action and relative weakness suggest the market is skeptical of the recovery story, despite analyst optimism. The single most important tension is whether the earnings recovery (forward EPS of $11.75) is durable or merely cyclical; if it proves sustainable, the stock is deeply undervalued, but if reimbursement pressures erode margins further, the forward multiple could prove illusory.
Bullish
- Deep value on forward earnings: CVS trades at a forward PE of just 10.14x versus a trailing PE of 56.69x, implying the market expects a dramatic earnings recovery. Analyst EPS estimates of $11.75 for the coming year suggest the forward multiple is well-supported, and the stock's PS ratio of 0.25x sits at the very bottom of its multi-year range (down from 1.78x in Q4 2021).
- Strong analyst consensus and upside: 25 analysts rate CVS a 'strong_buy' with a mean recommendation of 1.41 (where 1.0 is a strong buy) and an average target price of $116.28, implying 34.5% upside from the current $86.46. The low target of $103.00 still represents 19% upside, indicating that even the most cautious analysts see meaningful value.
- Profitability inflection and raised guidance: Q2 2026 net income reached $2.995 billion (2.82% net margin), a dramatic reversal from the -$3.975 billion loss in Q3 2025. The lower medical cost ratio drove a Q1 earnings beat and raised full-year guidance, and the favorable CMS Medicare Advantage rate decision added roughly $13 billion in revenue visibility.
- Solid free cash flow covers dividend: Trailing free cash flow of $11.76 billion comfortably covers the $878 million quarterly dividend and $691 million of quarterly capex. The 3.38% dividend yield is attractive for income investors, and the payout ratio is only about 29% of quarterly earnings, leaving room for continued shareholder returns.
Bearish
- Severe recent underperformance and momentum breakdown: CVS has fallen 11.08% over the past month and 17.44% over three months, massively underperforming SPY by 11.67 and 20.78 percentage points respectively. The stock sits at just 41.2% of its 52-week range ($69.51–$110.68), having surrendered the majority of its earlier advance.
- Structurally thin margins limit profitability: Gross margin is only 14.84% in Q2 2026, operating margin is 2.58%, and net margin is 2.82%, reflecting the low-margin nature of pharmacy and insurance revenue. These economics are typical for a managed-care/pharmacy hybrid, but they leave little buffer against reimbursement pressure or cost inflation.
- Leveraged balance sheet with tight liquidity: Debt-to-equity stands at 1.24 and the current ratio is just 0.84, indicating a leveraged, working-capital-tight operation. Quarterly interest expense of $757 million is a material fixed cost, and external financing conditions remain a swing factor for equity value.
- Regulatory and reimbursement headwinds persist: Persistent reimbursement pressure and regulatory scrutiny of PBM practices continue to weigh on the stock, as highlighted in recent news. The Zacks article notes that while operational improvements and AI integration are promising, these challenges make CVS a 'hold for now'.
CVS Technical Analysis
CVS is in a choppy, range-bound recovery rather than a clean uptrend, with a 1-year price change of +11.63% that masks significant internal volatility. At $86.46, the stock sits at roughly 41.2% of its 52-week range (low $69.51, high $110.68), meaning it has surrendered the majority of its earlier advance and is trading in the lower-middle portion of its annual band. That positioning is neither a momentum breakout nor a deep-value falling knife — it reflects a market that has repriced the turnaround story lower after a strong spring run, and it implies limited near-term cushion above the 52-week low relative to the distance back to the highs.
Short-term momentum has deteriorated sharply and is diverging bearishly from the longer-term trend: the 1-month change is -11.08% and the 3-month change is -17.44%, even as the 6-month change remains +17.65% and the 1-year change is +11.63%. This pattern — strong six-month gains erased by a brutal recent slide — signals that the spring rally (which peaked near $110.68 in late July) has given way to a sustained distribution phase, not a mere pause. Relative strength confirms the underperformance: CVS trails SPY by 11.67 percentage points over 1 month and 20.78 points over 3 months, while its 6-month relative strength is essentially flat at +0.30, indicating the entire outperformance was front-loaded and has now fully reversed.
Key technical levels are well defined: support sits at the 52-week low of $69.51, roughly 19.6% below the current $86.46, while resistance is the 52-week high of $110.68, about 28.0% above. A decisive break below the $85–$87 area (where the stock has repeatedly found bids in late September) would open the door to a retest of the $69.51 low, whereas reclaiming $95–$100 would be the first sign of trend repair. Volatility risk is comparatively modest — beta of 0.58 means CVS moves only about 58% as much as the market, which supports larger position sizing for risk-parity investors but also means the stock will lag in broad risk-on rallies; the -23.1% max drawdown underscores that low beta has not insulated holders from meaningful capital loss.
Beta
0.60
0.60x market volatility
Max Drawdown
-23.1%
Largest decline past year
52-Week Range
$70-$111
Price range past year
Annual Return
+14.0%
Cumulative gain past year
| Period | CVS Return | S&P 500 |
|---|---|---|
| 1m | -9.1% | +0.9% |
| 3m | -14.5% | +3.4% |
| 6m | +10.9% | +14.4% |
| 1y | +14.0% | +16.2% |
| ytd | +9.8% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CVS Fundamental Analysis
Revenue is growing at a healthy clip, with Q2 2026 revenue of $106.10 billion representing 7.26% year-over-year growth versus $98.92 billion in Q2 2025, continuing a steady multi-quarter climb from $100.43 billion in Q1 2026 and $105.69 billion in Q4 2025. The segment mix shows the growth engine clearly: pharmacy revenue of $60.83 billion and premiums of $35.12 billion dominate the top line, while front-store revenue of just $5.41 billion and other product/service revenue of $1.04 billion are comparatively marginal. This concentration means the investment case hinges on PBM volumes and Aetna membership economics rather than retail traffic, and the 7%+ growth rate — rare for a company of this scale — suggests the Medicare rate tailwind and script volumes are more than offsetting reimbursement headwinds.
Profitability has inflected decisively upward: Q2 2026 net income reached $2.995 billion with a 2.82% net margin, a dramatic reversal from the -$3.975 billion loss in Q3 2025 (a -3.86% net margin quarter driven by a $17.01 billion operating expense spike and negative EBITDA of -$1.564 billion). Gross margin, however, remains thin at 14.84% in Q2 2026 versus 15.56% in Q1 2026 and 12.84% in Q4 2025, and the trailing gross margin of 13.77% reflects the low-margin nature of pharmacy and insurance revenue. Operating margin of 2.58% and EBITDA of $5.86 billion show the company is solidly profitable but structurally constrained by its business mix — these are typical economics for a managed-care/pharmacy hybrid, where scale and cost control matter far more than pricing power.
Balance sheet and cash generation are adequate but not fortress-like: debt-to-equity of 1.24 and a current ratio of just 0.84 signal a leveraged, working-capital-tight operation, though trailing free cash flow of $11.76 billion comfortably covers the $878 million quarterly dividend and $691 million of quarterly capex. ROE of 2.35% and ROA of 2.97% are low in absolute terms, reflecting the capital intensity of the insurance and retail footprint, and the 3.38% dividend yield with a payout ratio of 192% of trailing EPS (though only ~29% of quarterly earnings) highlights the tension between shareholder returns and reinvestment. The company is generating enough internal cash to fund operations and dividends, but the 0.84 current ratio and $1.244 debt-to-equity mean external financing conditions and interest expense of $757 million per quarter remain material swing factors for equity value.
Quarterly Revenue
$106.1B
2026-06
Revenue YoY Growth
+7.3%
YoY Comparison
Gross Margin
14.8%
Latest Quarter
Free Cash Flow
$11.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CVS Overvalued?
Because CVS is profitable — Q2 2026 net income of $2.995 billion and trailing EPS of $0.0176 (distorted by prior-year losses) — the PE ratio is the appropriate primary metric, but the trailing figure of 56.69x is misleading given the earnings trough; the forward PE of 10.14x is far more informative. The enormous gap between trailing (56.69x) and forward (10.14x) multiples implies the market expects a dramatic earnings recovery, consistent with analyst EPS estimates of $11.75 for the coming year versus the depressed trailing base. On a price-to-sales basis, CVS trades at just 0.25x, and EV/Sales of 0.416x, both reflecting the low-margin, high-revenue nature of the business.
Against the healthcare plans industry, CVS screens as a deep-value proposition: a forward PE of 10.14x and PS of 0.25x are well below what managed-care peers typically command, and the PEG ratio of -0.918 (negative due to trailing loss distortions) further muddies traditional growth-adjusted comparisons. The discount appears partly justified by structurally lower gross margins (13.77% versus the higher-margin profile of pure-play insurers) and the complexity discount applied to conglomerates, but the 3.38% dividend yield and 0.42x EV/Sales suggest the market is pricing in substantial execution risk that the recent earnings beat and raised guidance may not warrant.
Historically, CVS's own valuation band has compressed dramatically: PE ratios ranged from 8.5x to 22.6x across 2022–2024, and PS ratios have fallen from 1.78x in Q4 2021 to 0.25x today — a roughly 86% compression in the sales multiple over four years. The current 0.25x PS sits at the very bottom of its multi-year range, while the forward PE of 10.14x is near the low end of its historical 8–23x band. This positioning suggests either a genuine value opportunity if the earnings recovery materializes, or a market that has permanently de-rated the stock due to structural pressures on pharmacy reimbursement and insurance margins — the resolution of that debate is the central question for investors.
PE
56.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 8x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.8x
Enterprise Value Multiple
Investment Risk Disclosure
CVS faces significant financial and operational risks. The company carries a debt-to-equity ratio of 1.24 and a current ratio of just 0.84, indicating a leveraged balance sheet with tight working capital. Quarterly interest expense of $757 million consumes a meaningful portion of operating income ($4.703 billion in Q2 2026), and any rise in borrowing costs could pressure earnings. Additionally, gross margin is thin at 14.84%, leaving little room for error if reimbursement rates decline or medical costs rise; the Q3 2025 loss of $3.975 billion demonstrates how quickly profitability can deteriorate. Revenue is concentrated in pharmacy ($60.83 billion) and premiums ($35.12 billion), making the company vulnerable to changes in PBM volumes or Aetna membership economics.
Market and competitive risks are substantial. CVS trades at a forward PE of 10.14x, which is below the broader market but reflects a permanent de-rating due to structural pressures on pharmacy reimbursement and insurance margins. The stock's beta of 0.58 means it is less volatile than the market, but it also lags in risk-on rallies, as evidenced by its 20.78 percentage point underperformance versus SPY over three months. Regulatory scrutiny of PBM practices remains a key overhang, and recent news highlights that persistent reimbursement pressures and regulatory challenges make the stock a 'hold for now'. Competitive disruption from online pharmacies and alternative care models could further erode CVS's retail and PBM dominance.
The worst-case scenario involves a combination of regulatory intervention that reduces PBM profitability, a resurgence in medical cost ratios that compresses insurance margins, and a failure to achieve the projected EPS recovery. In this scenario, the stock could retest its 52-week low of $69.51, representing a 19.6% decline from the current $86.46. If the low analyst target of $103.00 is breached due to a significant earnings miss, the downside could extend further, potentially to the $69–$75 range. Given the max drawdown of -23.1% over the past year, investors could lose approximately 20–25% from current levels in an adverse scenario, with the 52-week low serving as a key support level.
FAQ
The most severe risk is regulatory intervention in PBM practices, which could compress margins and reduce profitability. Financial risks include a leveraged balance sheet with debt-to-equity of 1.24 and a current ratio of 0.84, leaving little liquidity buffer. Operational risks stem from thin gross margins (14.84%) and exposure to medical cost inflation; a spike in the medical cost ratio could quickly erode earnings. Competitive risks include pressure from online pharmacies and alternative care models, as well as potential loss of major PBM contracts. Macroeconomic risks are moderate given the low beta of 0.58, but a recession could reduce healthcare spending and membership. Ranked by severity: regulatory, operational, financial, competitive.
Our 12-month forecast has three scenarios: a base case (50% probability) with a target range of $103–$116, assuming steady revenue growth and modest margin improvement; a bull case (30% probability) targeting $116–$148, driven by successful execution and multiple expansion; and a bear case (20% probability) targeting $69–$85, if regulatory or cost pressures derail the recovery. The most likely scenario is the base case, where CVS gradually recovers toward the analyst average target of $116.28 as earnings materialize. The key assumption is that forward EPS of $11.75 is achievable, which would justify a higher multiple. However, if the stock breaks below $85, the bear case becomes more probable.
CVS appears undervalued on both absolute and relative bases. Its forward PE of 10.14x is near the low end of its historical 8–23x range, and its PS ratio of 0.25x is at the very bottom of its multi-year range, down from 1.78x in Q4 2021. Compared to managed-care peers, CVS trades at a significant discount, partly due to its lower gross margin (14.84%) and conglomerate complexity. The market is pricing in substantial execution risk, but if the earnings recovery materializes (analyst EPS estimate of $11.75), the stock could re-rate toward 12–13x forward earnings, implying a price above $140. The current valuation suggests the market expects only modest growth, so any positive surprise could drive significant upside.
CVS presents a compelling risk/reward for value-oriented investors, with a forward PE of 10.14x and a 34.5% upside to the analyst average target of $116.28. The company has shown a strong profitability inflection, with Q2 2026 net income of $2.995 billion versus a loss in the prior-year quarter, and free cash flow of $11.76 billion comfortably covers its 3.38% dividend. However, the stock has fallen 17.44% over three months, and persistent reimbursement pressures and regulatory risks could delay the recovery. For long-term investors with a 2-3 year horizon, the deep value and dividend make it a good buy, but near-term volatility may test patience. A break below $85 would be a warning sign, while a reclaim of $95–$100 would confirm the bullish thesis.
CVS is better suited for long-term investment (minimum 2-3 years) given its turnaround nature and the time needed for the earnings recovery to fully materialize. The stock's low beta (0.58) and 3.38% dividend yield make it appropriate for income-oriented and defensive portfolios, but the recent 17.44% three-month decline and regulatory overhangs introduce near-term volatility that could frustrate short-term traders. Earnings visibility is improving but still uncertain, as evidenced by the Q3 2025 loss. A long-term holder can collect the dividend while waiting for the value thesis to play out, but short-term trading is risky given the lack of clear momentum. A suggested minimum holding period is 2 years to allow for the Medicare rate tailwind and cost efficiency initiatives to flow through.